Plasma Levels of miR-125b-5p and miR-206 in Acute Ischemic Stroke Patients After Recanalization Treatment: A Prospective Observational Study

Introduction: Multiple microRNAs (miRNAs) participate in the response to hypoxic/ischemic and ischemia-reperfusion events. However, the expression of these miRNAs in circulation from patients with acute ischemic stroke (AIS) receiving recanalization treatment has not been examined, and whether they are associated with the severity and outcome of stroke is still unknown. Materials and methods: In this prospective cohort study, plasma levels of miR-125b-5p, miR-15a-3p, miR-15a-5p, and miR-206 were measured at 24 hours after thrombolysis with or without endovascular treatment in 94 patients with AIS, as determined by qRT-PCR. Stroke severity was assessed based on National Institutes of Health Stroke Scale (NIHSS) score and infarct lesion. Intracranial haemorrhage (ICH) was recorded. An unfavorable outcome was defined as a modified Rankin Scale score greater than 2 at day 90 after stroke. Results: miR-125b-5p and miR-206 levels were correlated with NIHSS scores (P = .014 and P = .002) and cerebral infarction volumes (P = .025 and P = .030). miR-125b-5p levels were significantly higher in patients with an unfavorable outcome than in patients with a favorable outcome (P = .002) and showed good diagnostic accuracy in discriminating the presence of an unfavorable outcome (area under the curve .735, 95% confidence interval .623-.829, P < .001). No association was found between different miRNAs and ICH. Conclusions: In AIS patients after thrombolysis with or without endovascular treatment, miR-125b-5p is a novel prognostic biomarker highly associated with an unfavorable outcome. miR-125b-5p and miR-206 levels are associated with stroke severity.     

Simvastatin Alleviates Intestinal Ischemia/Reperfusion Injury by Modulating Omi/HtrA2 Signaling Pathways

PurposeThe objective of this research was to survey the therapeutic action of simvastatin (Sim) on intestinal ischemia/reperfusion injury (II/RI) by modulating Omi/HtrA2 signaling pathways.MethodsSprague Dawley rats were pretreated with 40 mg/kg Sim and then subjected to 1 hour of ischemia and 3 hours of reperfusion. The blood and intestinal tissues were collected, pathologic injury was observed, the contents of serum tumor necrosis factor-α and interleukin–6 (IL–6) were estimated, and superoxide dismutase, methane dicarboxylic aldehyde, and cysteinyl aspartate specific proteinase–3 (caspase–3) levels, as well as the expressions of Omi/HtrA2 and caspase–3, were measured in the intestinal tissues.ResultsSim preconditioning mitigated the damnification of intestinal tissues by decreasing oxidative stress, inflammatory damage, and apoptosis and downregulating the expression of Omi/HtrA2 compared to the ischemia/reperfusion group, while Sim+Ucf–101 significantly augmented this effect.ConclusionThese results suggest that Sim may alleviate intestinal ischemia/reperfusion injury by modulating Omi/HtrA2 signaling pathways.     

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC

IntroductionGut microbiome affecting the responses to immune checkpoint inhibitors against advanced NSCLC has been investigated in the Western population. However, considering pre-existing genetic and gut microbiota variation, the relevance remains unknown in the East-Asian NSCLC population. This study is designed to explore the relationship between gut microbiome and clinical outcomes in Chinese patients with NSCLC who have received treatment using an anti–programmed death 1 (PD-1) blockade.MethodsThirty-seven patients with advanced NSCLC receiving treatment with nivolumab were enrolled in CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, when patients received nivolumab, at clinical evaluation, and when disease progression was noted. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multicolor flow cytometry in parallel.ResultsWhen subgrouping patients into responder (R) and nonresponder according to the clinical response assessed using Response Evaluation Criteria in Solid Tumor version 1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival when compared to those with low diversity. Compositional difference was observed between the two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, and Prevotella copri in R whereas Ruminococcus_unclassified enriched in nonresponding patients. Analysis of systemic immune responses using multicolor flow cytometry revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8⁺ T cell and natural killer cell subsets in the periphery in response to anti–PD-1 therapy.ConclusionsOur results reveal strong correlation between gut microbiome diversity and the responses to anti–PD-1 immunotherapy in Chinese patients with advanced NSCLC. Patients with favorable gut microbiome (such as those with high diversity) exhibit enhanced memory T cell and natural killer cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti–PD-1 immunotherapy against NSCLC in the Chinese population.     

Chevron osteotomy versus scarf osteotomy for hallux valgus correction: A meta-analysis

BackgroundThis study intended to investigate the optimal surgical strategy in hallux valgus (HV), and to provide a basis for clinical treatment of HV.MethodsStudies related to chevron osteotomy and scarf osteotomy for HV were enrolled from online databases. Hallux valgus angle (HVA) was the main outcome variable. Enrolled studies included posttreatment data for intermetatarsal angle (IMA), American Orthopaedic Foot & Ankle Society (AOFAS) score, and complications. A random-effects model was applied for significant heterogeneity. Otherwise, a fixed-effects model was used. Heterogeneity was assessed with Q test and I² statistics. Publication bias was evaluated with Egger's test. Based on the influence of weighted mean difference values or odds ratios, a sensitivity analysis was performed.ResultsFour studies including 384 subjects were evaluated to determine the optimal surgical strategy for HV. There was no statistically significant difference between chevron and scarf groups for HVA, IMA, AOFAS score, and complication rates. Sensitivity analysis showed good stability. The likelihood of publication bias was small.ConclusionThe effects of chevron osteotomy and scarf osteotomy for HV are comparable. Chevron osteotomy is less technically demanding.     

通心络对急性脑梗死治疗作用基础与临床研究

目的通心络对急性脑梗死治疗作用的基础和临床研究。方法135例患者随机分成治疗组和对照组。治疗前后查Tin、t—PA、PAl、AⅢ、ACA、D—dinaer、tHey、Ps、Pc,并于15天、30天、90天行ESS和Barthel指数评分。结果与治疗前相比,治疗后两组患者血Till、PAl显著下降(P相似文献   

癌痛消胶囊调节小鼠荷H22移植性肝癌细胞VEGF表达的实验研究

目的 :通过观察癌痛消胶囊对小鼠荷H22 移植性肝癌细胞血管内皮细胞生长因子 (vascularendothelialgrowthfactor,VEGF)表达的调节作用 ,探讨该药抑制肿瘤的作用是否与抑制肿瘤血管生成有关。方法 :于昆明种雄性小鼠前肢右腋皮下接种0 2mlH22 肿瘤细胞悬液(浓度为1×107/ml)进行造模。利用造模动物观察瘤块重量 ,计算肿瘤生长抑制率 ,用免疫组化法检测瘤细胞中VEGF的表达程度。结果 :与阴性对照组相比 ,癌痛消胶囊组有明显的抑瘤作用(P<0 05) ,抑瘤率为36 34 % ;病理检测显示 ,造模各组VEGF阳性表达率为100% ,但程度不同 ,癌痛消胶囊组可使肿瘤组织VEGF的表达明显下调 ,与阴性对照组比较 ,差异有显著性意义(P<0 01)。结论 :癌痛消胶囊对小鼠荷H22 移植性肝癌细胞的生长有抑制作用 ,能减少血管生成调控基因VEGF的表达。     

血舒通治疗慢性肺原性心脏病并发重症心力衰竭的疗效观察

目的观察血舒通治疗慢性肺原性心脏病(简称肺心病)并发重症心力衰竭的临床疗效.方法 52例肺心病患者,随机分为地高辛联用速尿治疗组(对照组)和地高辛、速尿、血舒通联合治疗组(治疗组),疗程均为2周.结果 2周后总有效率:治疗组为92.3%、对照组为57.7%.两组疗效差异有显著性(P<0.01).结论在应用洋地黄及利尿剂的基础上加用血舒通,能明显提高肺心病重症心衰的疗效.     

通便玉蓉丸对便秘小鼠胃排空和小肠推进的影响

目的探讨通便玉蓉丸对便秘小鼠排便功能的影响,以阐明其治疗便秘的机理。方法将60只清洁级ICR小鼠随机分为空白组、模型组、麻仁润肠丸组、通便玉蓉丸大、中、小剂量组。经过造模、治疗,检测胃排空率和小肠碳末推进率。结果通便玉蓉丸促进胃排空作用明显,碳末推进百分率高,碳末移动距离延长,与模型组比较,有显著差异(P<0.05)。结论通便玉蓉丸通过提高胃排空率和小肠碳末推进率,能够增加排便治疗便秘。     

血塞通的不良反应

血塞通是三七总皂苷的纯中药制剂,具有降低机体耗氧、抑制血小板聚集、抗凝、抗血栓和扩张心脑血管等药理作用,主要用于缺血性脑血管疾病、脑出血后遗症、冠心病等的治疗。